Evaluation of the Potential Impact of Age- and Gender-Specific Lung Morphology and Ventilation Rate on the Dosimetry of Vapors

In recent years, there have been growing concerns that due to differences, both pharmacokinetic and pharmacodynamic, between children and adults, children could be at greater risk of adverse effects following chemical exposure. The specific goal of this study was to demonstrate an approach for using physiologically based pharmacokinetic (PBPK) modeling to compare inhalation dosimetry in the adult and the child of both males and females. Three categories of gases were considered: rapidly and irreversibly reactive in the respiratory tract (ozone), relatively water-soluble and nonreactive (isopropanol), and relatively water-insoluble and nonreactive (styrene, vinyl chloride, and perchloroethylene). The nonreactive chemicals were also selected because they are metabolized in the respiratory tract. The age-related changes observed for the estimated dose metrics were a function of the physiochemical properties of the inhaled vapor and their interactions in the body. Blood concentrations estimated for all vapors, either poorly metabolized (e.g., PERC), moderately metabolized (e.g., ST), or highly metabolized vapors (e.g., IPA and VC), varied less than a factor of two between infants and adults. These changes, moreover, were confined to the first year after birth, a relatively short window compared to the total lifespan of the individual. In contrast, circulating metabolite concentrations estimated in the blood, as well as amounts metabolized in the liver and lung, appeared to be a strong function of age, due to their dependence on the maturity of the pertinent metabolic enzyme systems.

[1]  M. Dunnill.  The problem of lung growth. , 1982, Thorax.

[2]  M Englert,et al.  [Pulmonary function testing]. , 1976, Bruxelles medical.

[3]  W. Jusko,et al.  Pharmacokinetics in the infant. , 1994, Environmental health perspectives.

[4]  W. Hofmann.  Mathematical model for the postnatal growth of the human lung. , 1982, Respiration physiology.

[5]  T. Martonen,et al.  Computer Simulations of Particle Deposition in the Developing Human Lung , 2000, Journal of the Air and Waste Management Association.

[6]  M. Andersen,et al.  PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF STYRENE AND STYRENE OXIDE RESPIRATORY-TRACT DOSIMETRY IN RODENTS AND HUMANS , 2002, Inhalation toxicology.

[7]  R. Phalen,et al.  Deposition of monodisperse particles in hollow models representing adult and child-size tracheobronchial airways. , 1997, Health physics.

[8]  H J Clewell,et al.  Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. , 1996, Toxicology.

[9]  D B Menzel,et al.  A model of the regional uptake of gaseous pollutants in the lung. I. The sensitivity of the uptake of ozone in the human lung to lower respiratory tract secretions and exercise. , 1985, Toxicology and applied pharmacology.

[10]  C. Kim,et al.  Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women. , 2000, Inhalation toxicology.

[11]  I. Ijiri,et al.  A statistical analysis of the internal organ weights of normal Japanese people. , 1997, Health physics.

[12]  Human respiratory tract model for radiological protection. A report of a Task Group of the International Commission on Radiological Protection. , 1994, Annals of the ICRP.

[13]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[14]  C. P. Yu,et al.  Predictive models for deposition of inhaled diesel exhaust particles in humans and laboratory species. , 1987, Research report.

[15]  F. J. Miller,et al.  A model of the regional uptake of gaseous pollutants in the lung. II. The sensitivity of ozone uptake in laboratory animal lungs to anatomical and ventilatory parameters. , 1987, Toxicology and applied pharmacology.

[16]  H J Clewell,et al.  Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. , 2001, The Science of the total environment.

[17]  K Walton,et al.  An analysis of the need for an additional uncertainty factor for infants and children. , 2000, Regulatory toxicology and pharmacology : RTP.

[18]  H J Clewell,et al.  Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[19]  R. Phalen,et al.  Postnatal enlargement of human tracheobronchial airways and implications for particle deposition , 1985, The Anatomical record.

[20]  T. Cresteil,et al.  Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. , 1996, European journal of biochemistry.

[21]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[22]  W. Bennett,et al.  Variability of fine particle deposition in healthy adults: effect of age and gender. , 1996, American journal of respiratory and critical care medicine.

[23]  D. Swift.  Age-related scaling for aerosol and vapor deposition in the upper airways of humans. , 1989, Health physics.

[24]  F. J. Miller,et al.  Upper respiratory tract surface areas and volumes of laboratory animals and humans: considerations for dosimetry models. , 1997, Journal of toxicology and environmental health.

[25]  Swift Dl.  Age-related scaling for aerosol and vapor deposition in the upper airways of humans. , 1989 .

[26]  H J Clewell,et al.  Variability of physiologically based pharmacokinetic (PBPK) model parameters and their effects on PBPK model predictions in a risk assessment for perchloroethylene (PCE). , 1993, Toxicology letters.

[27]  C B Frederick,et al.  Application of a hybrid computational fluid dynamics and physiologically based inhalation model for interspecies dosimetry extrapolation of acidic vapors in the upper airways. , 1998, Toxicology and applied pharmacology.

[28]  Raymond A. Guilmette,et al.  Morphometry of Human Nasal Airways In Vivo Using Magnetic Resonance Imaging , 1989 .

[29]  S H Moolgavkar,et al.  Two-stage model for carcinogenesis: Epidemiology of breast cancer in females. , 1980, Journal of the National Cancer Institute.

[30]  M E Andersen,et al.  A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors: analysis at steady state. , 1981, Toxicology and applied pharmacology.

[31]  P. Ohlin,et al.  Nasal mucosal blood flow at rest and during exercise. , 1985, Acta oto-laryngologica.

[32]  J. Morris,et al.  A physiologically based pharmacokinetic model for nasal uptake and metabolism of nonreactive vapors. , 1993, Toxicology and applied pharmacology.

[33]  M Pelekis,et al.  Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds. , 2001, Regulatory toxicology and pharmacology : RTP.

[34]  P. Pikkarainen,et al.  Development of Alcohol Dehydrogenase Activity in the Human Liver , 1967, Pediatric Research.

[35]  W. S. Snyder,et al.  Report of the task group on reference man , 1979, Annals of the ICRP.

[36]  C. Kim,et al.  Regional deposition of inhaled particles in human lungs: comparison between men and women. , 1998, Journal of applied physiology.

[37]  D. Lamb,et al.  Airspace size in lungs of lifelong non-smokers: effect of age and sex. , 1993, Thorax.

[38]  C. Bearer,et al.  How are children different from adults? , 1995, Environmental health perspectives.

[39]  Harvey J. Clewell,et al.  Review and Evaluation of the Potential Impact of Age- and Gender-Specific Pharmacokinetic Differences on Tissue Dosimetry , 2002, Critical reviews in toxicology.

[40]  R. Sarangapani,et al.  Analysis of vinyl acetate metabolism in rat and human nasal tissues by an in vitro gas uptake technique. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.